Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 1;27(7):1057–1066. doi: 10.1093/jamia/ocaa066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — Clinical trial curation workflow and results. The figure above shows (A) a broad overview of the curation workflow. There are currently 67 479 cancer-related clinical trials loaded into the system (as of 10/30/2019). Of these, 15 578 were found to have a status of recruiting or not-yet-recruiting. Of these, 9855 trials were automatically flagged for manual review as possibly containing biomarker key words. According to the curation SOP, of the 9855 manually reviewed clinical trials, 5045 met criteria for manual curation of disease-biomarker eligibility criteria and treatment context. A total of 4810 trials were considered out of scope based on the curation SOP. The trials that had a biomarker-driven eligibility criterion were curated. To date, we have manually curated and created structured annotations for 5045 clinical trials. A detailed copy of the SOP is provided in the Supplementary Material. Trials included for manual curation have a recruiting status of “Recruiting” or “Not yet recruiting,” that are (i) interventional (ii) directed toward treating cancer (not for treating side-effects or toxicities caused by cancer treatments), and (iii) contain biomarker-driven eligibility criteria (patient’s tumor is required to have a specific biomarker to enroll on the trial). (B) the different biomarker type supported by the system for clinical trial curation. Genomic biomarker makes up the largest category followed by protein, cytogenetic, viral, serological, and epigenetic-related biomarkers. The numbers in parentheses on the X-axis indicate the actual number of defined concepts in each category, while the instances of cumulative use across clinical trial curations are shown on the y-axis. The curated trial dataset (n = 5045) was used to calculate these numbers.